摘要
在慢性病毒感染和肿瘤中,耗竭的CD_(8)^(+) T细胞是阻碍病毒及肿瘤得到有效控制的关键因素。这种细胞的主要特征之一就是多种抑制性受体的共同表达,因此目前临床上的免疫治疗策略主要是通过阻断这些抑制性受体来恢复其功能。然而,免疫检查点阻断(ICB)疗法仅使少数患者受益。近年来的研究揭示了耗竭CD_(8)^(+) T细胞群体中存在多种具有不同生物学特性的亚群,因此人们越来越关注选择性地靶向这些不同的亚群,并改变它们原有的分化轨迹,从而提高ICB疗法反应率的可能性。本文总结了慢性感染和肿瘤中耗竭的CD_(8)^(+) T细胞异质性的相关研究,概述了耗竭的CD_(8)^(+) T细胞中各亚群的动态演变过程,并强调了探索其异质性对推动免疫疗法进一步发展的重要作用。
In the chronic viral infections and tumors,CD_(8)^(+) T cell exhaustion is a critical factor to influence an optimal control of viruses and tumors.Co-expression of multiple inhibitory receptors are the major characteristic of CD8+T cells.Therefore,contemporary immunotherapeutic approaches are largely centered on inhibiting these receptors to rejuvenate cell functionality.However,immune checkpoint blockade(ICB)therapy is only efficacious on a limited population.Recent studies have shown that the pool of exhausted CD_(8)^(+) T cells is composed of multiple subsets with varied biological characteristics.There is a growing interest in the possibility of selectively targeting these distinct subpopulations and modifying their inherent differentiation paths to improve the hyporesponsiveness of ICB therapy.This article consolidated findings on the heterogeneity of exhausted CD_(8)^(+) T cells in chronic infections and cancers,delineated the dynamic progression of these subpopulations,and underscored the significance of investigating this diversity to propel the development of immunotherapy.
作者
王睿
罗华婷
谭桂丽
秦波
WANG Rui;LUO Huating;TAN Guili(Department of Infectious Diseases,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China;不详)
出处
《河北医药》
2025年第7期1192-1196,1201,共6页
Hebei Medical Journal
基金
重庆市自然科学基金(编号:cstc2020jcyj-msxmX0221)。
